PT3514235T - Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento - Google Patents
Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamentoInfo
- Publication number
- PT3514235T PT3514235T PT181524224T PT18152422T PT3514235T PT 3514235 T PT3514235 T PT 3514235T PT 181524224 T PT181524224 T PT 181524224T PT 18152422 T PT18152422 T PT 18152422T PT 3514235 T PT3514235 T PT 3514235T
- Authority
- PT
- Portugal
- Prior art keywords
- composition
- utilisation
- medicament
- treatment
- ulcerative colitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18152422.4A EP3514235B8 (de) | 2018-01-18 | 2018-01-18 | Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3514235T true PT3514235T (pt) | 2024-02-12 |
Family
ID=61054138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT181524224T PT3514235T (pt) | 2018-01-18 | 2018-01-18 | Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento |
Country Status (11)
Country | Link |
---|---|
US (2) | US20210177883A1 (pt) |
EP (1) | EP3514235B8 (pt) |
JP (2) | JP2021511310A (pt) |
KR (1) | KR20200110684A (pt) |
CN (1) | CN111630169A (pt) |
BR (1) | BR112020014583A8 (pt) |
CA (1) | CA3088576A1 (pt) |
ES (1) | ES2973216T3 (pt) |
PT (1) | PT3514235T (pt) |
RU (1) | RU2020127436A (pt) |
WO (1) | WO2019141674A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4408396A1 (en) | 2021-09-30 | 2024-08-07 | Sterna Biologicals GmbH | Dnazyme hydrogel formulations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2294988C (en) * | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
DE10346487A1 (de) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
EP2708898A1 (de) * | 2012-09-14 | 2014-03-19 | Sterna Biologicals GmbH & Co. Kg | Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten |
BR112017006272A2 (pt) * | 2014-09-29 | 2018-03-13 | Ea Pharma Co., Ltd. | composição farmacêutica para tratar colite ulcerativa. |
US10905710B2 (en) * | 2016-05-24 | 2021-02-02 | Emory University | Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders |
-
2018
- 2018-01-18 EP EP18152422.4A patent/EP3514235B8/de active Active
- 2018-01-18 ES ES18152422T patent/ES2973216T3/es active Active
- 2018-01-18 PT PT181524224T patent/PT3514235T/pt unknown
-
2019
- 2019-01-15 CN CN201980009283.7A patent/CN111630169A/zh active Pending
- 2019-01-15 WO PCT/EP2019/050923 patent/WO2019141674A1/de active Application Filing
- 2019-01-15 US US16/962,849 patent/US20210177883A1/en not_active Abandoned
- 2019-01-15 BR BR112020014583A patent/BR112020014583A8/pt not_active Application Discontinuation
- 2019-01-15 CA CA3088576A patent/CA3088576A1/en active Pending
- 2019-01-15 RU RU2020127436A patent/RU2020127436A/ru unknown
- 2019-01-15 KR KR1020207023637A patent/KR20200110684A/ko not_active Ceased
- 2019-01-15 JP JP2020539047A patent/JP2021511310A/ja active Pending
-
2023
- 2023-08-17 JP JP2023133181A patent/JP2023156463A/ja active Pending
- 2023-10-17 US US18/488,067 patent/US20240041912A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019141674A1 (de) | 2019-07-25 |
JP2021511310A (ja) | 2021-05-06 |
RU2020127436A (ru) | 2022-02-21 |
EP3514235B8 (de) | 2024-02-14 |
US20240041912A1 (en) | 2024-02-08 |
BR112020014583A2 (pt) | 2020-12-01 |
ES2973216T3 (es) | 2024-06-19 |
CA3088576A1 (en) | 2019-07-25 |
CN111630169A (zh) | 2020-09-04 |
EP3514235A1 (de) | 2019-07-24 |
JP2023156463A (ja) | 2023-10-24 |
EP3514235B1 (de) | 2024-01-03 |
US20210177883A1 (en) | 2021-06-17 |
BR112020014583A8 (pt) | 2022-08-30 |
KR20200110684A (ko) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
IL276398A (en) | Combined treatment for mastocytosis | |
PT3277295T (pt) | Composição para o tratamento de um estado metabólico patogénico da flora intestinal e de doenças derivadas | |
IL260955A (en) | A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure | |
GB2590793B (en) | Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy | |
IL282007A (en) | Medicine to treat chronic cough | |
IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
IL286000A (en) | Asketamine for the treatment of depression | |
SG11202110480YA (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
IL282904A (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis | |
HUE058250T2 (hu) | Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére | |
IL283898A (en) | Medical clamping device for attaching implants | |
IL279054A (en) | Adeno-associated virus vectors for the treatment of mucopolysacridoses type IV A | |
IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
PT3514235T (pt) | Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento | |
HK1257590A1 (zh) | 預防和治療藥物性腎損傷的藥物及其用途 | |
EP3534924A4 (en) | COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF HEART CIRCULAR DISEASES | |
IL280243A (en) | Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure | |
IL276228A (en) | Compounds and preparations for the treatment of pain | |
IL265976A (en) | Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions | |
HUE053866T2 (hu) | Gyógyászati készítmény székrekedés kezelésére | |
PL3618806T3 (pl) | Kompozycja do leczenia aft i owrzodzeń jamy ustnej | |
EP3490604C0 (en) | MEDICATION FOR THE TREATMENT AND/OR PREVENTION OF ENDOMETRIOSIS | |
GB201901130D0 (en) | Formulation for the treatment of tendinopathies |